Jasper Therapeutics (JSPR) Analyst & Key Data

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

8

Hold

5

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$0.66

Median Target+278.62%

$2.50

Potential upside vs current price

DCF Value+75.25%

$1.16

Potential upside vs current price

Current Stock Price

$0.66

Median Target+278.62%

$2.50

Potential upside vs current price

DCF Value+75.25%

$1.16

Potential upside vs current price

Analyst Consensus

Buy2 analysts

Buy

Updated Sep 12, 2026

Total Analysts2

Buy

8

Hold

5

Ratings

Updated Sep 12, 2026

Overall Rating

C+

DCF Score5.0 / 5

Debt / Equity Score3.0 / 5

Price / Book Score1.0 / 5

Price / Earnings Score1.0 / 5

ROA Score1.0 / 5

ROE Score1.0 / 5

Valuation

Current Stock Price

$0.66

Median Target+278.62%

$2.50

Potential upside vs current price

DCF Value+75.25%

$1.16

Potential upside vs current price

Current Stock Price

$0.66

Median Target+278.62%

$2.50

Potential upside vs current price

DCF Value+75.25%

$1.16

Potential upside vs current price

Jasper Therapeutics, Inc.